Metronomic chemotherapy is a modality of chemotherapy in which patients receive more frequently a drug at a lower dosage. It began as a means to treat unfit patients (elderly or severely ill) and as palliative therapy. Due to it’s lower toxicity and better safety profile, it has been extrapolated also to fit patients who have also a curative chance and since then it has been studied.
This type of chemotherapy is based upon the concept of giving patients a consistent blood serum level of chemotherapy through a longer period of time. In regular chemotherapy, patients get a high dose of chemo in larger intervals (usually every 2-3 week cycle), so there is a huge burst of chemotherapy inside the body, which fades away and there is a long period in which there is no chemo left inside the bloodstream and, consequently, in the cancer cells.
Chemotherapy is one of the pillars of anti-neoplastic therapy and can be used against most types of cancer. This way of administering the drugs tries to minimize its side effects and the “downtime” in order to keep the drug’s serum levels constant through a longer period of time and keep cancer cells always under stress and maximize the treatment’s efficiency.
We believe that metronomic chemotherapy may be used for a number of different patients and is a helpful tool when combined with other treatment modalities in the fight against cancer. It is mostly safe with patients experiencing normally only mild side effects (which vary depending on the chemotherapy involved). It may be done orally or through an intravenous infusion